THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ:OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that the Company will report financial results for the three months ended September 30, 2015 after the close of trading on Tuesday, November 10th.
Opexa Therapeutics to Host Analyst and Investor Event
In addition, Opexa will host an Analyst and Investor Event on November 10th where members of Opexa’s senior management team will provide an R&D update and review of the Company’s Abili-T clinical trial for secondary progressive multiple sclerosis and the development program for neuromyelitis optica. The Analyst and Investor Event will take place at the New York Hilton Midtown, Concourse E, 1335 6th Ave (between 53rd and 54th), New York, New York. Guest speakers at the event include two key opinion leaders in the fields of multiple sclerosis and neuromyelitis optica:
-
Clyde Markowitz, M.D.
- Associate Professor of Neurology at the Hospital of The University of Pennsylvania
-
Benjamin Greenberg, M.D., M.H.S
- Associate Professor of Neurology, University of Texas, Southwestern Medical Center
- Department of Neurology & Neurotherapeutics, Pediatrics
A live webcast of the event will start at 5:15 p.m. Eastern Time and may be accessed here, or on the Investor Relations section of the Company’s website, www.opexatherapeutics.com. The event should conclude by 7:00 p.m. An archived version of the webcast will be available for 90 days after the event on the Company’s website.
About Opexa
Opexa is a biopharmaceutical company developing a personalized immunotherapy with the potential to treat major illnesses, including multiple sclerosis (MS) as well as other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa’s proprietary T-cell technology. The Company’s leading therapy candidate, Tcelna®, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of secondary progressive MS. Tcelna consists of myelin-reactive T-cells, which are expanded ex vivo from the patient’s peripheral blood and reintroduced into the patient in an attenuated form via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin for each individual patient.
For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com or follow company news on Twitter via @OpexaCEO.
